Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

BACKGROUND: Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction (HFpEF)....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cardiovasc Diabetol
Autori principali: Bode, David, Semmler, Lukas, Wakula, Paulina, Hegemann, Niklas, Primessnig, Uwe, Beindorff, Nicola, Powell, David, Dahmen, Raphael, Ruetten, Hartmut, Oeing, Christian, Alogna, Alessio, Messroghli, Daniel, Pieske, Burkert M., Heinzel, Frank R., Hohendanner, Felix
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792219/
https://ncbi.nlm.nih.gov/pubmed/33413413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01208-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi